Experience pTau and beyond with the NULISAseq CNS Disease Panel 120 for detection of 120 important CNS disease related proteins with unrivaled sensitivity, plex, and simplicity.
Meet with us at booth #936 and get a demo of the ARGO HT System or schedule time with one of us for a personal demo and to discuss your research goals.
Thomas Karikari, PhD#361: Plasma proteomic changes in carriers of progranulin mutations on the novel NULISA platform
J. Simrén, PhD, et al. University of Gothenburg
Multi-analyte measurement of blood biomarkers for Alzheimer’s disease: enabling concurrent analysis of affected pathophysiological processes
Xuemei Zeng PhD, et al. University of Pittsburgh
Molecular biomarkers for Alzheimer’s Disease and related dementias – improved methods to facilitate global studies
Henrik Zetterberg, MD, PhD, University of Gothenburg
CSF and Plasma Proteomics in the AT groups. What is beyond amyloid and p-tau?
Andrea L. Benedet, PhD, et al. University of Gothenburg
#236: Plasma biomarkers discrimination accuracy of biologically defined Alzheimer’s disease in a memory clinic setting
Frederica Anastasi, PhD, et al.
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation
#266: Plasma proteomic profiling in mild cognitive impairment using NULISAseq
Guglielmo Di Molfetta, PhD, et al. University of Gothenburg
#328: Inflammation links in Alzheimer’s Disease: connecting fluid proteomics and TSPO PET
Ilaria Pola, PhD, et al.
University of Gothenburg
#351: Determining APOE ε4 carriership by NUcleic acid Linked Immuno-Sandwich Assay
Kübra Tan, PhD, et al.
University of Gothenburg
#847: Validation of the plasma phosphorylated tau quantified using NUcleic acid Linked Immuno-Sandwich Assay (NULISA) for the detection of Alzheimer’s disease pathology
Yi-Ting Wang
McGill University Research Centre for Studies in Aging
#315: Development of NULISAseq™ CNS Disease Panel 120 for comprehensive proteomics profiling of neurodegenerative diseases
Xiao-Jun Ma, PhD, et al. Alamar Biosciences
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.